FDA Approval of Tepotinib: A Comparative Analysis with Capmatinib

This chapter explores the FDA approval of tepotinib for treating metastatic non-small cell lung cancer, comparing it to capmatinib. The discussion includes their pharmacology, dosing, side effects, and ongoing research, shedding light on their efficacy and suitability for patient treatment plans.